Can we use Ki67 expression to predict prostate cancer aggressiveness?

Abstract

Introduction: specialists have an urge for biomarkers that can discriminate indolent prostate cancer from aggressive tumors. Ki67 is a proliferation marker, and its expression is associated with the aggressiveness of several cancers. Objective: analyze the expression of Ki67 in prostate cancer samples correlating with the aggressiveness of the disease. Methods: Ki67 mRNA levels were determined utilizing data from a TCGA cohort (Tumor(n)=492 and control(n)=52). The protein expression was determined on 94 biopsies from patients by immunohistochemical assay. Results: in mRNA, the Ki67 upregulation is associated with cancer tissue (p<0.0001) and worst disease-free survival (p=0.035). The protein upregulation is associated with increase of the ISUP score (p<0.0001), cancer stage (p=0.05), biochemical recurrence (p=0.0006) and metastasis (p<0.0001). We also show a positive correlation between Ki67 expression and ISUP score (r=0.5112, p<0.0001) and disease risk stratification (r=0.3388, p=0.0009). Ki67 expression is a factor independently associated with biochemical recurrence (p=0.002) and metastasis (p<0.0001). Finally, the patients with high Ki67expression shows better survival regarding biochemical recurrence (p=0.008) and metastasis (p=0.056). Patients with high Ki67 expression are 2.62 times more likely to develop biochemical recurrence (p=0.036). Conclusion: Ki67 upregulation is associated with prostate cancer aggressiveness.

The copper (II) complex of salicylate phenanthroline inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells

“…The results demonstrated that Cu(sal)(phen) remarkably delayed tumor growth, decreased the size of tumors in mice, and downregulated the expression of antiapoptotic Bcl-2 and survivin proteins in the tumor, which was in agreement with the results of in vitro experiments. Ki67 is strongly associated with tumorigenesis,30 and we found that the expression level of Ki67 in tumors was downregulated by Cu(sal)(phen) treatment. Collectively, the antitumor effect of Cu(sal)(phen) could be attributed to inhibitingF I G U R E 6The body weights of mice treated with different concentrations of Cu(sal)phen for 14 days.…”